Abstract
Due to the lack of the acid 1,4-α-glucosidase, the urine of Pompe patients contains increased levels of specific glucose tetrasaccharide αGlc(1 → 6)αGlc(1 → 4)αGlc(1 → 4)Glc (Glc4), which was approved as a non-invasive biomarker of glycogen accumulation in the muscles of Pompe patients. MALDI-TOF mass spectrometry and 1H NMR spectroscopy were used for Glc4 detection in the urine samples of four Pompe patients with infantile, juvenile, and adult forms of the disease, before and during, or before and after, enzyme replacement therapy. The increased sensitivity and decreased urine volume required for Glc4 detection by MALDI-TOF mass spectrometry was obtained by specific derivatization directly on the MALDI plate by 3-aminoquinoline. This method is a suitable and fast method for Pompe screening. 1H NMR spectra, used for precise Glc4 quantifications, were proposed for the enzyme replacement therapy efficiency monitoring. Besides the clinical features and the biochemical parameters, knowledge about the evolution of the Glc4 levels over time during the administration of the therapy could help monitoring of the patient outcome as part of the standard protocol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A, Sullivan JA, Hoganson GE, Phillips JA, Schaefer GB, Charrow J, Ware RE, Bossen EH, Chen YT (2001) Recombinant human acid a-glucosidase enzyme therapy for infants with glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3:132–138
An Y, Young SP, Hillman SL, van Hove JLK, Chen YT, Millington DS (2000) Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. Anal Biochem 287(1):136–143. https://doi.org/10.1006/abio.2000.4838
An Y, Young SP, Kishnani PS, Millington DS, Amalfitato A, Corzo D, Chen YT (2005) Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disese. Mol Genet Metabol 85(4):247–254. https://doi.org/10.1016/j.ymgme.2005.03.010
Bauer S (2012) Mass spectrometry for characterizing plant cell wall polysaccharides. Front Plant Sci 3:45. https://doi.org/10.3389/fpls.2012.00045
Bergsma AJ, In’t Groen SL, Verheijen FW, van der Ploeg AT, Pijnappel WP (2016) From cryptic toward canonical pre-mRNA splicing in Pompe disease: a pipeline for the development of antisense oligonucleotides. Mol Ther Nucleic Acids 5(9):e361. https://doi.org/10.1038/mtna.2016.75
Bonesso L, Piraud M, Caruba C, van Obberghen E, Mengual R, Hinault Ch (2014) Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry. Orph J Rare Dis 9:19. https://doi.org/10.1186/1750-1172-9-19
Burton BK (2012) Newborn screening for Pompe disease: an update. Am J Med Genet C Semin Med Genet 160C(1):8–12. https://doi.org/10.1002/ajmg.c.31315
Casado M, Altimira L, Montero R, Castejón E, Nascimento A, Pérez-Duenas B, Ormazabal A, Artuch R (2014) A capillary electrophoresis procedure for the screening of oligosaccharidoses and related diseases. Anal Bioanal Chem 406(18):4337–4343. https://doi.org/10.1007/s00216-014-7832-6
Casado M, Ferrer-López I, Ruiz-Sala P, Pérez-Cerdá C, Artuch R (2017) Urine oligosaccharide tests fot the diagnosis of oligosaccharidoses. Rev Anal Chem. https://doi.org/10.1515/revac-2016-0019
Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, Wu MH, Huang PH, Tsai FJ, Chen YT, Hwu WL (2009) Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 124(6):e1116–e1125. https://doi.org/10.1542/peds.2008-3667
Chien YH, Lee NCh, Chen ChA, Tsai FJ, Tsai WH, Shieh JY, Huang HJ, Hsu WCh, Tsai TH, Hwu WL (2015a) Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr 166(4):985–991.e1–2. https://doi.org/10.1016/j.jpeds.2014.10.068
Chien YH, Goldstein JL, Hwu WL, Smith PB, Ni-Chung L, Chiang SCh, Tolun AA, Zhang H, Vaisnins AE, Millington DS, Kishnani PS, Young SP (2015b) Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening. JIMD Reports 19:67–73. https://doi.org/10.1007/8904_2014_366
Dasouki M, Jawdat O, Amdhoun O, Pasnoor M, McVey AL, Auzinadah A, Herbelin L, Barohn J, Dimachkie MM (2014) Pompe disease: literature review and case series. Neurol Clin 32(3):751–776. https://doi.org/10.1016/j.ncl.2014.04.010
de Almeida Thomazinho P, Scalco FB, de Oliveira MLC, Horovitz DDG, Llerena JC Jr (2017) Motor development as a potential marker to monitor infantile Pompe disease on enzyme replacement therapy. Open J Clin Diagnostics 7(1):8–19. https://doi.org/10.4236/ojcd.2017.71002
Domon B, Costello CE (1988) A systematic nomenclature for carbohydrate fragmentation in FAB-MS/MS spectra of glycoconjugates. Glycoconjugate J 5(4):397–409. https://doi.org/10.1007/BF01049915
Gowda GAN, Djukovic D, fan Bettcher L, Gu H, Raftery D (2018) NMR-guided mass spectrometry for absolute quantitation of human blood metabolites. Anal Chem 90:2001–2009. https://doi.org/10.1021/acs.analchem.7b04089
Hallgren P, Hansson G, Henriksson KG, Häger A, Lundblad A, Svensson S (1974) Increased excretion of a glucose-containing tetrasaccharide in the urine of a patient with glycogen storage disease type II (Pompe’s disease). Eur J Clin Investig 4(6):429–433
Huang CK, Liao HC, Hsieh YP, Chen YC, Yang FC, Niu DM (2015) Glucose tetrasaccharide (Glc4) level in urine sample as a biomarker for Pompe patients. Ann Transl Med 3(S2):AB067. https://doi.org/10.3978/j.issn.2305-5839.2015.ab067
Kaneshiro K, Fukuyama Y, Iwamoto S, Sekiya S, Tanaka K (2011) Highly sensitive MALDI analyses of glycans by a new aminoquinoline-labeling method using 3-aminoquinoline/α-cyano-4-hydroxycinnamic acid liquid matrix. Anal Chem 83(10):3663–3667. https://doi.org/10.1021/ac103203v
Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg AT, Clancy JP, Parini R, Morin G, Beck M, de la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE (2007) Recombinant human acid alpha-glucosidase: major clinical benefits in infantile onset Pompe disease. Neurology 68(2):99–109. https://doi.org/10.1212/01.wnl.0000251268.41188.04
Kishnani PS, Amartino HM, Lindberg Ch, Miller TM, Wilson A, Kreutzer J (2014) Methods of diagnosing of patients with Pompe disease: data from the Pompe registry. Mol Gen and Metabolism 113(1–2):84–91. https://doi.org/10.1016/j.ymgme.2014.07.014
Kumlien J, Grönberg G, Nilsson B, Mänsson O, Zopf D, Lundblad A (1989) Structural and immunochemical analysis of three α-limit dextrin oligosaccharides. Arch Biochem Biophys 269(2):678–689
Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden Rizopoulos, Brusse E, van Doorn PA, van der Ploeg AT, van der Beek N (2017) Long-term benefit of enzyme replacement therapy in Pompe disease. A 5-year prospective study. Neurology 89(23):2365–2373. https://doi.org/10.1212/wnl.0000000000004711
Lim JA, Li L, Raben N (2014) Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci 6:177. https://doi.org/10.3389/fnagi.2014.00177
Lobato JB, Parejo PD, Diez PT, Jimenez LM (2013) Glucosa tetrasacárido como biomarcador diagnóstico de la enfermedad de Pompe: estudio en 35 pacientes. Med Clin Barc 141(3):106–110. https://doi.org/10.1016/j.medcli.2013.02.035
Manwaring V, Prunty H, Bainbridge K, Burke D, Finnegan N, Franses R, Lam A, Vellodi A, Heales S (2012) Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases. J Inh Metab Dis 35:311–316. https://doi.org/10.1007/s10545-011-9360-2
Pakanová Z, Matulová M, Behúlová D, Šalingová A, Hlavatá A, Pätoprstý V, Mucha J (2016) Molecular diagnosis of Pompe disease using MALDI TOF/TOF and 1H NMR. Chem Pap 70(3):265–271. https://doi.org/10.1515/chempap-2015-0218
Pérez-López J, Selva-O’Callaghan A, Grau-Junyent JM, Gallego-Galindo L, Coll MJ, García-Morillod S, Torralba-Cabeza MA, Vilardell-Tarrés M (2015) Delayed diagnosis of late-onset Pompe disease in patients with myopathies of unknown origin and/or hyperCKemia. Mol Genet Metab 114(4):580–583. https://doi.org/10.1016/j.ymgme.2015.02.004
Rohmer M, Meyer B, Mank M, Stahl B, Bahr U, Karas M (2010) 3-Aminoquinoline acting as matrix and derivatizing agent for MALDI MS analysis of oligosaccharides. Anal Chem 82(9):3719–3726. https://doi.org/10.1021/ac1001096
Rozaklis T, Ramsay SL, Whitfield PD, Ranieri E, Hopwood JJ, Meikle PJ (2002) Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry. Clin Chem 48(1):131–139
Safdar A, Nilsson M, Akhtar M, Tarnopolsky M (2016) Exosome-mRNA (EXERNA) therapy for Pompe disease. Mol Genet Metab 117:S100. https://doi.org/10.1016/j.ymgme.2015.12.422
Schielen PCJI, Kemper EA, Gelb MH (2017) Newborn screening for lysosomal storage diseases: a concise review of the literature on screening methods, therapeutic possibilities and regional programs. Int J Neonat Screen 3(2):6. https://doi.org/10.3390/ijns3020006
Schoser B, Bilder DA, Dimmock D, Gupta D, James ES, Prasad S (2017) The humanistic burden of Pompe disease: are there still unmet needs? A systematic review. BMC Neurol 17:202. https://doi.org/10.1186/s12883-017-0983-2
Sluiter W, van den Bosch JC, Goudriaan DA, van Gelder CM, de Vries JM, Huijmans JGM, Reuser AJJ, van der Ploeg AT, Ruijter GJG (2012) Rapid ultraperformance liquid chromatography–tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases. Clin Chem 58(7):1139–1147. https://doi.org/10.1373/clinchem.2011.178319
So K, Iizuka S, Kobayashi H, Kimura T, Fukuda T, Shen J, Shimada Y, Ida H, Eto Y, Ohashi T (2010) Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction. Gene Ther 17(4):521–530. https://doi.org/10.1038/gt.2009.160
Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, Deschauer M, Breunig F, Glocker FX, Vielhaber S, Brejova A, Hilz M, Reiners K, Müller-Felber W, Mengel E, Spranger M, Schoser B (2010) Enzyme replacement theraphy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12 month results of an observational clinical trial. J Neurol 257(1):91–97. https://doi.org/10.1007/s00415-009-5275-3
Szájli E, Fehér T, Medzihradszky KF (2008) Investigating the quantitative nature of MALDI-TOF MS. Mol Cel Proteomics 7(12):2410–2418. https://doi.org/10.1074/mcp.M800108-MCP200
van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, de Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, van Hirtum H, van Diggelen OP, Boer M, Kroos MA, van Doorn PA, van der Voort E, Sibbles B, van Corven EJ, Brakenhoff JP, van Hove J, Smeitink JA, de Jong G, Reuser AJ, van der Ploeg AT (2004) Long-term intravenous treatment of Pompe disease with recombinant human alfa-glucosidase from milk. Pediatrics 113(5):e448–e457
van der Ploeg AT, Reuser AJ (2008) Pompe’s disease. Lancet 372(9646):1342–1353. https://doi.org/10.1016/S0140-6736(08)61555-X
van Til NP, Stok M, Aerts Kaya FS, de Waard MC, Farahbakhshian E, Visser TP, Kroos MA, Jacobs EH, Willart MA, van der Wegen P, Scholte BJ, Lambrecht BN, Duncker DJ, van der Ploeg AT, Reuser AJ, Verstegen MM, Wagemaker G (2010) Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. Blood 115(26):5329–5337. https://doi.org/10.1182/blood-2009-11-252874
Xia B, Asif G, Arthur L, Pervaiz MA, Li X, Liu R, Cummings RD, He M (2013) Oligosaccharide analysis in urine by MALDI-TOF mass spectrometry for the diagnosing of lysosomal storage diseases. Clin Chem 59(9):1357–1368. https://doi.org/10.1373/clinchem.2012.201053
Xu F, Ding E, Migone F, Serra D, Schneider A, Chen YT, Amalfitano A (2005) Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA. J Gene Med 7(2):171–178. https://doi.org/10.1002/jgm.660
Young SP, Zhang H, Corzo D, Thurbewrg BL, Bali D, Kishnani PS, Millington DS (2009) Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med 11(7):536–541. https://doi.org/10.1097/GIM.0b013e3181a87867
Young SP, Piraud M, Goldstein JL, Zhang H, Rehder C, Laforet P, Kishnani PS, Millington DS, Bashir MR, Bali DS (2012) Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Am J Med Genet Part C Semin Med Gen 160C(1):50–58. https://doi.org/10.1002/ajmg.c.31320
Acknowledgements
Financial support from VEGA 2/0130/18, VEGA 2/0188/14 and APVV-15-0410 grant are acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pakanová, Z., Matulová, M., Uhliariková, I. et al. Case study: monitoring of Glc4 tetrasaccharide in the urine of Pompe patients, use of MALDI-TOF MS, and 1H NMR. Chem. Pap. 73, 701–711 (2019). https://doi.org/10.1007/s11696-018-0623-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11696-018-0623-3